EDUCATION

Medical School

  • Harvard Medical School , Boston , MA

Internship

Pediatrics
  • Boston Children's Hospital , Boston , MA

Residency

Chief Medical Resident
  • Boston Children's Hospital , Boston , MA

Fellowship

Pediatric Critical Care Medicine
  • Boston Children's Hospital , Boston , MA

Fellowship

Pediatric Infectious Disease
  • Boston Children's Hospital , Boston , MA

Fellowship

Research, Microbiology, Immunology
  • Brigham and Women’s Hospital , Boston , MA

CERTIFICATIONS

  • American Board of Pediatrics, Critical Care Medicine
  • American Board of Pediatrics, General Pediatrics

PUBLICATIONS

Publications powered by Harvard Catalyst Profiles

  1. The Role of Anesthetic Management in Surgical Site Infections After Pediatric Intestinal Surgery. J Surg Res. 2021 Mar; 259:546-554. View abstract
  2. Stress ulcer prophylaxis versus placebo-a blinded randomized control trial to evaluate the safety of two strategies in critically ill infants with congenital heart disease (SUPPRESS-CHD). Trials. 2020 Jun 29; 21(1):590. View abstract
  3. Central venous catheter bundle adherence: Kamishibai card (K-card) rounding for central-line-associated bloodstream infection (CLABSI) prevention. Infect Control Hosp Epidemiol. 2020 Sep; 41(9):1058-1063. View abstract
  4. Genomic and epidemiological evidence of bacterial transmission from probiotic capsule to blood in ICU patients. Nat Med. 2019 11; 25(11):1728-1732. View abstract
  5. Multidisciplinary Quality Improvement Intervention to Achieve Sustained Improvement in Hand Hygiene Reliability in a Pediatric Intensive Care Unit. Pediatr Qual Saf. 2019 Nov-Dec; 4(6):e227. View abstract
  6. Calm in the midst of cytokine storm: a collaborative approach to the diagnosis and treatment of hemophagocytic lymphohistiocytosis and macrophage activation syndrome. Pediatr Rheumatol Online J. 2019 Feb 14; 17(1):7. View abstract
  7. Whole-Genome Sequences of Staphylococcus aureus Isolates from Cystic Fibrosis Lung Infections. Microbiol Resour Announc. 2019 Jan; 8(3). View abstract
  8. Progress Toward the Elusive Pseudomonas aeruginosa Vaccine. Surg Infect (Larchmt). 2018 Nov/Dec; 19(8):757-768. View abstract
  9. Variability in antimicrobial use in pediatric ventilator-associated events. Infect Control Hosp Epidemiol. 2019 01; 40(1):32-39. View abstract
  10. PLGA-encapsulation of the Pseudomonas aeruginosa PopB vaccine antigen improves Th17 responses and confers protection against experimental acute pneumonia. Vaccine. 2018 11 12; 36(46):6926-6932. View abstract
  11. Construction of a Protective Vaccine Against Lipopolysaccharide-Heterologous Pseudomonas aeruginosa Strains Based on Expression Profiling of Outer Membrane Proteins During Infection. Front Immunol. 2018; 9:1737. View abstract
  12. A putative lateral flagella of the cystic fibrosis pathogen Burkholderia dolosa regulates swimming motility and host cytokine production. PLoS One. 2018; 13(1):e0189810. View abstract
  13. Ceftaroline pharmacokinetics and pharmacodynamics in patients with cystic fibrosis. J Cyst Fibros. 2018 05; 17(3):e25-e31. View abstract
  14. Factors Associated With Pediatric Ventilator-Associated Conditions in Six U.S. Hospitals: A Nested Case-Control Study. Pediatr Crit Care Med. 2017 Nov; 18(11):e536-e545. View abstract
  15. Incident Stenotrophomonas maltophilia infection and lung function decline in cystic fibrosis. Pediatr Pulmonol. 2017 10; 52(10):1276-1282. View abstract
  16. Immune Recognition of the Epidemic Cystic Fibrosis Pathogen Burkholderia dolosa. Infect Immun. 2017 06; 85(6). View abstract
  17. From the Cover: Prolonged Exposure to Volatile Anesthetic Isoflurane Worsens the Outcome of Polymicrobial Abdominal Sepsis. Toxicol Sci. 2017 04 01; 156(2):402-411. View abstract
  18. Global and local selection acting on the pathogen Stenotrophomonas maltophilia in the human lung. Nat Commun. 2017 01 19; 8:14078. View abstract
  19. An Oxygen-Sensing Two-Component System in the Burkholderia cepacia Complex Regulates Biofilm, Intracellular Invasion, and Pathogenicity. PLoS Pathog. 2017 01; 13(1):e1006116. View abstract
  20. A Pediatric Approach to Ventilator-Associated Events Surveillance. Infect Control Hosp Epidemiol. 2017 03; 38(3):327-333. View abstract
  21. 1015: IDENTIFICATION OF PEDIATRIC VENTILATOR-ASSOCIATED CONDITIONS USING CONTINUOUS VENTILATOR DATA. Crit Care Med. 2016 Dec; 44(12 Suppl 1):330. View abstract
  22. 1214: PEDIATRIC VENTILATOR-ASSOCIATED CONDITIONS ARE RARELY ASSOCIATED WITH INFECTION. Crit Care Med. 2016 Dec; 44(12 Suppl 1):379. View abstract
  23. Efficacy of Antibody to PNAG Against Keratitis Caused by Fungal Pathogens. Invest Ophthalmol Vis Sci. 2016 12 01; 57(15):6797-6804. View abstract
  24. Enteral Nutrition and Acid-Suppressive Therapy in the PICU: Impact on the Risk of Ventilator-Associated Pneumonia. Pediatr Crit Care Med. 2016 10; 17(10):924-929. View abstract
  25. Ventilator-Associated Events in Neonates and Children--A New Paradigm. Crit Care Med. 2016 Jan; 44(1):14-22. View abstract
  26. Intestinal Microbiota of Mice Influences Resistance to Staphylococcus aureus Pneumonia. Infect Immun. 2015 Oct; 83(10):4003-14. View abstract
  27. Impact of Mandatory Public Reporting of Central Line-Associated Bloodstream Infections on Blood Culture and Antibiotic Utilization in Pediatric and Neonatal Intensive Care Units. Infect Control Hosp Epidemiol. 2015 Aug; 36(8):878-85. View abstract
  28. Strategies to prevent ventilator-associated pneumonia in acute care hospitals: 2014 update. Infect Control Hosp Epidemiol. 2014 Sep; 35 Suppl 2:S133-54. View abstract
  29. Microbiota-driven immune cellular maturation is essential for antibody-mediated adaptive immunity to Staphylococcus aureus infection in the eye. Infect Immun. 2014 Aug; 82(8):3483-91. View abstract
  30. Vaccines for Pseudomonas aeruginosa: a long and winding road. Expert Rev Vaccines. 2014 Apr; 13(4):507-19. View abstract
  31. Genetic variation of a bacterial pathogen within individuals with cystic fibrosis provides a record of selective pressures. Nat Genet. 2014 Jan; 46(1):82-7. View abstract
  32. Trehalose biosynthesis promotes Pseudomonas aeruginosa pathogenicity in plants. PLoS Pathog. 2013 Mar; 9(3):e1003217. View abstract
  33. Disinfection of needleless connectors with chlorhexidine-alcohol provides long-lasting residual disinfectant activity. Am J Infect Control. 2013 Aug; 41(8):e77-9. View abstract
  34. Collaboration between macrophages and vaccine-induced CD4+ T cells confers protection against lethal Pseudomonas aeruginosa pneumonia during neutropenia. J Infect Dis. 2013 Jan 01; 207(1):39-49. View abstract
  35. Hepoxilin A(3) facilitates neutrophilic breach of lipoxygenase-expressing airway epithelial barriers. J Immunol. 2012 Nov 15; 189(10):4960-9. View abstract
  36. Topical neutralization of interleukin-17 during experimental Pseudomonas aeruginosa corneal infection promotes bacterial clearance and reduces pathology. Infect Immun. 2012 Oct; 80(10):3706-12. View abstract
  37. Th17-stimulating protein vaccines confer protection against Pseudomonas aeruginosa pneumonia. Am J Respir Crit Care Med. 2012 Sep 01; 186(5):420-7. View abstract
  38. Targeting pan-resistant bacteria with antibodies to a broadly conserved surface polysaccharide expressed during infection. J Infect Dis. 2012 Jun; 205(11):1709-18. View abstract
  39. Parallel bacterial evolution within multiple patients identifies candidate pathogenicity genes. Nat Genet. 2011 Nov 13; 43(12):1275-80. View abstract
  40. Mucosal vaccination with a multivalent, live-attenuated vaccine induces multifactorial immunity against Pseudomonas aeruginosa acute lung infection. Infect Immun. 2011 Mar; 79(3):1289-99. View abstract
  41. Analysis of acquisition of Pseudomonas aeruginosa gastrointestinal mucosal colonization and horizontal transmission in a murine model. J Infect Dis. 2010 Jan 01; 201(1):71-80. View abstract
  42. Caveolin-1 modifies the immunity to Pseudomonas aeruginosa. J Immunol. 2010 Jan 01; 184(1):296-302. View abstract
  43. Inescapable need for neutrophils as mediators of cellular innate immunity to acute Pseudomonas aeruginosa pneumonia. Infect Immun. 2009 Dec; 77(12):5300-10. View abstract
  44. IL-17 is a critical component of vaccine-induced protection against lung infection by lipopolysaccharide-heterologous strains of Pseudomonas aeruginosa. J Immunol. 2008 Oct 01; 181(7):4965-75. View abstract
  45. The neutrophil serine protease inhibitor serpinb1 preserves lung defense functions in Pseudomonas aeruginosa infection. J Exp Med. 2007 Aug 06; 204(8):1901-9. View abstract
  46. A live-attenuated Pseudomonas aeruginosa vaccine elicits outer membrane protein-specific active and passive protection against corneal infection. Infect Immun. 2006 Feb; 74(2):975-83. View abstract
  47. Sepsis in the immunocompromised child: the least studied with the most to gain. Pediatr Crit Care Med. 2005 May; 6(3 Suppl):S78-9. View abstract
  48. Virulence of Pseudomonas aeruginosa in a murine model of gastrointestinal colonization and dissemination in neutropenia. Infect Immun. 2005 Apr; 73(4):2262-72. View abstract
  49. Human monoclonal antibodies to Pseudomonas aeruginosa alginate that protect against infection by both mucoid and nonmucoid strains. J Immunol. 2004 Nov 01; 173(9):5671-8. View abstract
  50. The galU Gene of Pseudomonas aeruginosa is required for corneal infection and efficient systemic spread following pneumonia but not for infection confined to the lung. Infect Immun. 2004 Jul; 72(7):4224-32. View abstract
  51. Protection against fatal Pseudomonas aeruginosa pneumonia in mice after nasal immunization with a live, attenuated aroA deletion mutant. Infect Immun. 2003 Mar; 71(3):1453-61. View abstract
  52. Vaccines for Pseudomonas aeruginosa. In: Ellis RW, Brodeur BR, editors. New bacterial vaccines. 2003; 261-283. View abstract
  53. Construction and characterization of a live, attenuated aroA deletion mutant of Pseudomonas aeruginosa as a candidate intranasal vaccine. Infect Immun. 2002 Mar; 70(3):1507-17. View abstract
  54. High-frequency oscillatory ventilation in pediatric patients. Respir Care Clin N Am. 2001 Dec; 7(4):633-45. View abstract
  55. The effect of human serum DNAases on the ability to detect antibiotic-killed Escherichia coli in blood by PCR. J Med Microbiol. 2001 Mar; 50(3):243-248. View abstract
  56. Acquisition of expression of the Pseudomonas aeruginosa ExoU cytotoxin leads to increased bacterial virulence in a murine model of acute pneumonia and systemic spread. Infect Immun. 2000 Jul; 68(7):3998-4004. View abstract
  57. Bacterial subretinal abscess: a case report and review of the literature. Am J Ophthalmol. 2000 Jun; 129(6):778-85. View abstract
  58. Continuous improvement learning for residents. Pediatrics. 1998 Apr; 101(4 Pt 2):768-73; discussion 773-4. View abstract